A Trial of Sugemalimab and Chemotherapy in Unresectable Stage III NSCLC

The goal of this phase II, open-label, single-arm study is to evaluate the efficacy and safety of induction immunotherapy and chemotherapy followed by the multidisciplinary team (MDT)-guided radiotherapy or surgery in unresectable, stage III non-small cell lung cancer.

Trial Details

NCT ID
NCT05940532
Phase
PHASE2
Sponsor
Hunan Cancer Hospital
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • Sugemalimab and Chemotherapy
Locations (sample)
  • Changsha, China|28.19874,112.97087

Key Eligibility Criteria

  • 18 to 75 years old, both male and female;
  • ECOG score: 0-1;
  • Histopathologically or cytologically confirmed, stage III (AJCC 8th) non-small cell lung cancer;
  • Multidisciplinary team (MDT) discussion confirmed unresectable disease but can be treated by curative radiotherapy;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →